Tumor Biology, Immunotherapy and Immune Prevention in Lynch Syndrome

Explore tumor biology, immunotherapy, and immune prevention strategies specifically related to Lynch syndrome through this comprehensive medical session from the Dana-Farber Cancer Institute. Delve into the constitutional MLH1 methylation (epimutation) and its role in Lynch syndrome pathogenesis with insights from leading research at H.Lee Moffitt Cancer Center. Examine the latest advances in treatment approaches for Lynch syndrome-associated cancers, including current therapeutic protocols and emerging treatment modalities from Memorial Sloan Kettering Cancer Center. Investigate the cutting-edge research on vaccine-based tumor prevention strategies specifically designed for Lynch syndrome patients, analyzing current progress and future potential from University of Kansas Cancer Center. Learn about immune checkpoint inhibitor therapy applications in non-metastatic colorectal cancer, including patient selection criteria, treatment protocols, and clinical outcomes from Mayo Comprehensive Cancer Clinic. Participate in an interactive panel discussion where leading experts address clinical questions and discuss practical applications of these advanced therapeutic approaches in Lynch syndrome management.